JCN Network - Home
JCN Newswire
 Search:    Companies  | Annual Reports  |  CSR  | News Alerts  |  Japanese   
Company
News Sectors
Automotive
Chemicals
Consumers
CSR
Electronics
Energy
Environment
Financial
Health & Med
Industrial
IT & Internet
Materials
Real Estate
Science & Tech
Telecoms
Trade
Transportation
Departments
Annual Reports
Companies
Trade Shows
News Alerts
News Search
Photo Gallery
Japan Corporate News Network
About JCN
Privacy Policy
RSS  
Terms of Use
 
Bookmark and Share
European Commission Grants Marketing Authorization for Eisai's Zonegran
 

Tokyo, Mar 18, 2005 (JCN) - Eisai announced on March 16 that its UK subsidiary Eisai Ltd. has received marketing authorization for Zonegran from the European Commission (EC) as of March 10.

This authorization allows the product to be marketed in EU countries for the adjunctive treatment for partial seizures of adult epilepsy patients.

Developed by Eisai, the zonisamide agent Zonegran is currently marketed in the US and Japan (trade name Excegran). By adding the product to its line of nerve drugs, the company aims to meet patients' needs and increase its presence in the EU.


By Aki Tsukioka Contributor

Copyright © 2010 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Eisai News  RSS  
  Eisai Submits Application for Additional Indication of Anti-arrhythmic Agent Tambocor(R) Tablets for Tachyarrhythmia in Paediatric Patients in Japan  (Jan 14, 2010)
  Submission of a New Drug Application for Pancreatic Enzyme Replacement Therapy Agent SA-001 in Japan  (Dec 24, 2009)
  Eisai Launches New Oral Jelly Formulation of Aricept(R), World's First Oral Jelly for Alzheimer's Disease Treatment  (Dec 1, 2009)
  Eisai and Quintiles Enter into a Strategic Collaboration to Develop Eisai's Anticancer Compounds  (Oct 30, 2009)
  Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival  (Oct 30, 2009)
  Eisai and TSD Japan Enter into a License and Joint Development Agreement of Denileukin Diftitox in Japan  (Oct 26, 2009)
  Eisai Opens Regional Office in Bahrain  (Oct 16, 2009)
  Abbott and Eisai Submit Application for Approval of Humira(R) for the Treatment of Crohn's Disease in Japan  (Sept 30, 2009)
  Eisai and DNDi Enter Collaboration and License Agreement to Develop New Drug for Chagas Disease  (Sept 29, 2009)
  Eisai Submits Application for Additional Indication of its Proton Pump Inhibitor PARIET(R) for Non-erosive GERD in Japan  (Sept 29, 2009)



 Recent  Health/Medical News   RSS  
Asahi Kasei Integrates Bioprocess Businesses in North America (Dec 31, 2009)
Asahi Kasei Kuraray Medical Establishes Sales Subsidiary in Korea (Nov 1, 2009)
Asahi Kasei Launches 'Reveal DX' Insertable Cardiac Monitor (Oct 1, 2009)
New RIKEN Robot to Assist in Care Facilities (Sept 29, 2009)
Asahi Kasei Kuraray Medical Building Plant for Therapeutic Apheresis Devices (Sept 25, 2009)
Teijin Develops World's First Bioplastic Eyeglasses (Sept 4, 2009)
Astellas Establishes Fund Laboratory 'Genome Medical Science Laboratory' at the University of Tokyo (Sept 4, 2009)
Kuraray Mediacal Obtains Approval for Artificial Bone Graft (Sept 2, 2009)
Daiichi Sankyo, Ranbaxy Launch Psteoporosis Medication EVISTA in Romania (Sept 2, 2009)
Pfizer and Astellas to Co-promote Hypertension, Hypercholesterolemia Treatment (Aug 31, 2009)

More Health/Medical news...

 Recent  Health/Medical News   RSS  
Asahi Kasei Integrates Bioprocess Businesses in North America (Dec 31, 2009)
Asahi Kasei Kuraray Medical Establishes Sales Subsidiary in Korea (Nov 1, 2009)
Asahi Kasei Launches 'Reveal DX' Insertable Cardiac Monitor (Oct 1, 2009)
New RIKEN Robot to Assist in Care Facilities (Sept 29, 2009)
Asahi Kasei Kuraray Medical Building Plant for Therapeutic Apheresis Devices (Sept 25, 2009)
Teijin Develops World's First Bioplastic Eyeglasses (Sept 4, 2009)
Astellas Establishes Fund Laboratory 'Genome Medical Science Laboratory' at the University of Tokyo (Sept 4, 2009)
Kuraray Mediacal Obtains Approval for Artificial Bone Graft (Sept 2, 2009)
Daiichi Sankyo, Ranbaxy Launch Psteoporosis Medication EVISTA in Romania (Sept 2, 2009)
Pfizer and Astellas to Co-promote Hypertension, Hypercholesterolemia Treatment (Aug 31, 2009)

More Health/Medical news...
 
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)